B of A Securities Initiates Coverage On Iambic Therapeutics with Buy Rating, Announces Price Target of $30
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsInitiationPrice Target
B of A Securities analyst Alec Stranahan initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Buy rating and announces Price Target of $30.
B of A Securities analyst Alec Stranahan initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Buy rating and announces Price Target of $30.